Document Detail

Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
MedLine Citation:
PMID:  17426205     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: L-[3-(18)F]-alpha-methyltyrosine ((18)F-FMT) is an amino-acid tracer for positron emission tomography (PET) and is used for tumor detection because malignant tumor cells accumulate (18)F-FMT based on the increased expression of an amino-acid transporter. This study was conducted to investigate the usefulness of (18)F-FMT PET in combination with fluorine-18-fluorodeoxyglucose ((18)F-FDG) PET for the diagnosis of sarcoidosis in patients with suspected malignancy. SETTING: Twenty-four sarcoidosis patients with suspected malignancy underwent (18)F-FDG and (18)F-FMT PET. The study included 17 patients with extrapulmonary manifestation mimicking malignant disease (13 patients with systemic lymphadenopathy, 3 of them with concomitant hepatosplenic processes; 3 patients with hepatosplenic processes without concomitant lymphadenopathy; and 1 patient with multiple bone lesions), 3 patients with occurrence of bilateral hilar lymphadenopathy in cancer patients, and 4 patients with multiple nodules mimicking pulmonary metastasis. RESULTS: All patients showed increased uptake of (18)F-FDG and no increase in the accumulation of (18)F-FMT in their lymphadenopathy. Standardized uptake values (SUVs) of (18)F-FDG and (18)F-FMT were 5.01 +/- 2.15 and 0.77 +/- 0.24, respectively (mean +/- SD). All extranodal lesions such as liver, spleen, and bone were visually positive on (18)F-FDG PET and negative on (18)F-FMT PET. No neoplasm was confirmed in all patients. In a control group of patients with lung cancer, SUVs for (18)F-FDG and (18)F-FMT were 6.34 +/- 2.52 and 1.54 +/- 0.82, respectively. CONCLUSION: The uptake of (18)F-FDG was positive in the sarcoid lesions, and therefore (18)F-FDG PET could not differentiate sarcoidosis from malignant disease. Use of (18)F-FMT PET in combination with (18)F-FDG PET may be the effective method to distinguish sarcoidosis from malignancy.
Kyoichi Kaira; Noboru Oriuchi; Yoshimi Otani; Noriko Yanagitani; Noriaki Sunaga; Takeshi Hisada; Tamotsu Ishizuka; Keigo Endo; Masatomo Mori
Related Documents :
1859075 - T lymphocyte activation in patients with active tuberculosis.
9282635 - Hla association with sarcoidosis and diffuse interstitial pulmonary fibrosis.
7718835 - Cerebral tuberculosis in the immunocompetent host: 8 cases observed in switzerland.
6657915 - Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients.
7781555 - Myelopathies in ethiopia.
7102425 - Atraumatic rcbf measurement: an aid in the timing of surgery and the management of spas...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chest     Volume:  131     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-11     Completed Date:  2007-05-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1019-27     Citation Subset:  AIM; IM    
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma 371-8511, Japan.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Diagnosis, Differential
Fluorine Radioisotopes
Fluorodeoxyglucose F18 / diagnostic use*
Lung Neoplasms / diagnosis
Methyltyrosines / diagnostic use*
Middle Aged
Radiopharmaceuticals / diagnostic use*
Reproducibility of Results
Sarcoidosis / radionuclide imaging*
Tomography, Emission-Computed, Single-Photon / methods*
Reg. No./Substance:
0/3-fluoro-alpha-methyltyrosine; 0/Fluorine Radioisotopes; 0/Methyltyrosines; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chest ultrasonography for the diagnosis and monitoring of high-altitude pulmonary edema.
Next Document:  Ability of low-dose helical CT to distinguish between benign and malignant noncalcified lung nodules...